[Effectiveness of a new beta 2-agonist (broxaterol) on bronchospasm induced by methacholine (blind study versus salbutamol)].
A new beta 2-agonists, broxaterol, administered by oral spray has been tested to evaluate its action modifying on the bronchial hyperreactivity to metacholine. Such drug has been administered double blind Vs salbutamol individualizing for both, at 15' and 90' premedication the PD20 FEV1 (doses of metacholine necessary to reduce of 20% the FEV1). The results that we have obtained confirm the protective capacity for both drugs on the bronchoconstriction induced by aspecific stimulus. However, in confront with salbutamol, the broxaterol presents an action more lasting in the time. Such requisite and absence of collateral effects permit to affirm that this new beta 2-agonists is fit for its utilization in the infantile intrinsic asthma.
Corrias
A
A
Istituto di Clinica Pediatrica - Servizio di Allergologia ed Immunologia Infantile dell'Università di Cagliari, Italia.
Corona
G B
GB
Pelosi
U
U
Corda
R
R
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000420:Albuterol / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy; D001986:Bronchial Spasm / Q000139:chemically induced / Q000188:drug therapy*; D002648:Child; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D005541:Forced Expiratory Volume; D006801:Humans; D007555:Isoxazoles / Q000627:therapeutic use*; D008297:Male; D008688:Methacholine Compounds; D010080:Oxazoles / Q000627:therapeutic use*; D013997:Time Factors
D000318:Adrenergic beta-Agonists; D007555:Isoxazoles; D008688:Methacholine Compounds; D010080:Oxazoles; D000420:Albuterol; C045916:broxaterol
Efficacia di un nuovo beta 2-agonista (broxaterolo) sul broncospasmo indotto da metacolina (studio in cieco verso salbutamolo).